OPDIVO®
(nivolumab) Patient Alert Card

IMPORTANT - This card contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab(Yervoy®). Keep this card with you in your wallet and show it to any healthcare professional involved in your treatment, not just your prescribing specialist doctor. It is important that you keep this card for at least 5 months after completing your treatment.

Date of Preparation: May 2017 1506UK1700458-02

Bristol-Myers Squibb
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com
**OPDIVO® (nivolumab)**

This card contains important information. Always carry this card with you and show it if you need to consult another doctor (for example if you are travelling).

Tell your doctor right away if you have any of these symptoms or any other symptoms

---

### LUNGS
- Breathing difficulties, cough

### BOWEL and STOMACH
- Diarrhoea (watery, loose or soft stools), blood or mucus in your stools, dark-coloured stools, pain or tenderness in your stomach or abdominal area

### LIVER
- Eye or skin yellowing (jaundice), pain on the right side of your stomach area, tiredness

### KIDNEYS
- Decreased amount of urine

### DIABETES/DIABETIC KETOACIDOSIS
- Excessive thirst, increased appetite with a loss of weight, tiredness, weakness, drowsiness, depression, irritability, feeling unwell, increased amount of urine

### SKIN
- Severe skin reactions, like skin rash with or without itching, blisters and/or peeling of the skin (possibly fatal), ulcers, dry skin, skin nodules

### HORMONE-PRODUCING GLANDS
- Headaches, blurry or double vision, fatigue, tiredness, weight changes, behavioural changes (e.g. less sex drive, irritability or forgetfulness)

### MUSCLES (including heart)
- Signs and symptoms of myositis (inflammation of the muscles), myocarditis (inflammation of the heart muscle), and rhabdomyolysis (breakdown of skeletal muscle), which may include muscle pain, stiffness, weakness, chest pain, irregular heartbeat, palpitations, confusion, decreased amount of urine, dark urine, or severe fatigue

### OTHER
- Eye pain or redness, blurry vision, or other vision problems; upper abdominal pain (inflammation of the pancreas), decreased appetite, nausea or vomiting; indigestion or heartburn; tingling or numbness in arms and legs or difficulty walking; fever, swollen lymph nodes; signs or symptoms of inflammation of the brain, which may include headache, fever, seizures, stiff neck, tiredness, confusion, weakness or drowsiness

---

**IMPORTANT**
- Early management of side effects reduces the likelihood that treatment with nivolumab or nivolumab in combination with ipilimumab (Yervoy) will need to be temporarily or permanently stopped, allowing patients to get the maximum benefit from treatment.
- Symptoms that may appear mild can quickly worsen if left untreated.
- Don’t try to treat these symptoms yourself.

**TELL YOUR DOCTOR IMMEDIATELY IF YOU:**
- Know you are allergic to nivolumab or any other medicine or medicine ingredients
- Have an autoimmune disease
- Have melanoma of the eye
- Have experienced side effects with another drug, such as ipilimumab
- Have been told your cancer has spread to your brain
- Have taken medicines to suppress your immune system. Nivolumab may cause solid organ transplant rejection
- Have any history of inflammation of the lungs
- Are pregnant or planning to become pregnant, or are breast-feeding
- Are taking or have taken any other medicines
- Are on a low salt diet

For further information, consult the Opdivo Package Leaflet, which can be found at www.medicines.org.uk/emc or call Bristol-Myers Squibb Medical Information on 0800 731 1736
This patient is treated with nivolumab or nivolumab in combination with ipilimumab.

Immune-related adverse reactions (irARs), may appear at any time during the treatment or months after its discontinuation.

Early diagnosis and appropriate management are essential to minimise life-threatening complications. Nivolumab specific management guidelines for irARs are available.

If you are a doctor who is not a specialist in oncology, please contact an Oncologist.